Eagle Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Eagle Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Eagle Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Eagle Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Eagle Pharmaceuticals Inc (Eagle Pharmaceuticals) is a pharmaceutical company that focuses on developing and commercializing treatments for critical care and oncology patients. It offers proprietary pharmaceutical injectables in the therapy areas of critical care, oncology, and various orphan diseases. The company’s commercial products include pharmaceutical injectables, including Ryanodex for exertional heatstroke, Bendeka, and Belrapzo, for the treatment of chronic lymphocytic leukemia, and indolent B-cell non-Hodgkin’s lymphoma. Its pipeline products include CAL-02 for the treatment of severe community-acquired bacterial pneumonia, ENA-001 for respiratory depression, and EA-114 for the treatment of hormone-receptor-positive metastatic breast cancer. The company’s products cater to patients and healthcare professionals in the areas of critical care, orphan diseases, and oncology. Eagle Pharmaceuticals is headquartered in Woodcliff Lake, New Jersey, the US.
Headquarters
United States of America
Address
50 Tice Boulevard, Suite 315, Woodcliff Lake, New Jersey, 07677
Website
www.eagleus.com
Telephone
1 201 3265300
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
EGRX (OTC)
Revenue (2022)
$316.6M
84.6%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
513.1%
(2022 vs 2021)
Market Cap*
$16.7M
Net Profit Margin (2022)
XYZ
323.9%
(2022 vs 2021)
* As of and is in US$
Eagle Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Marketed | Ryanodex |
| Ryanodex - Malignant Hyperthermia | Belrapzo |
| Belrapzo - Chronic Lymphocytic Leukemia & B-cell Non-Hodgkin's Lymphoma | Barhemsys |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In October, the company entered into an agreement with Eagle Pharmaceuticals to secure financial assistance for patients prescribed Eagle’s Pemfexy to manage and treat lung cancer. |
| 2023 | Contracts/Agreements | In April, the company signed an agreement with Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc. related to its new drug application referencing BENDEKA. |
| 2022 | Regulatory Approval | In November, the company's investigational new drug application accepted by the US Food and Drug Administration for CAL02, a novel first-in-class broad-spectrum anti-virulence agent for the adjunct treatment of severe community-acquired bacterial pneumonia. |
Competitor Comparison
| Key Parameters | Eagle Pharmaceuticals Inc | CTI BioPharma Corp | Spectrum Pharmaceuticals Inc | Elite Laboratories Inc | Endo International Plc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | Ireland |
| City | Woodcliff Lake | Seattle | Lake Forest | Northvale | Dublin |
| State/Province | New Jersey | Washington | Illinois | New Jersey | Dublin |
| No. of Employees | - | 128 | 86 | - | 2,931 |
| Entity Type | Public | Private | Private | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Michael Graves | Chairman; Chief Executive Officer | Executive Board | 2016 | - |
| Christopher Krawtschuk | Chief Financial Officer | Senior Management | 2024 | - |
| Daniel O'Connor | Chief Strategy Officer; Head - Corporate Development | Senior Management | 2019 | - |
| Debra M. Hussain | Head - Care/Hospital | Senior Management | 2022 | - |
| Reed McClung | Executive Vice President - Oncology Business Development | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer